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Brian Godman reviews the paper by Vogler and colleagues on the procurement of generics or 
originators among European hospitals once multiple sources become available. 
 
Vogler and colleagues have provided valuable insight into the procurement of generic medicines in 
hospitals among medium-sized European countries [1]. To date, this has been a neglected area with 
the majority of research and payer focus on ambulatory care as medicine expenditure in hospitals has 
only been a limited proportion of overall hospital expenditure at 5% to 10% over the years [1], whilst 
pharmaceutical expenditure in ambulatory care is typically the second highest cost component after 
physician salaries, with expenditures rising by more than 50% in real terms during the past decade 
[2]. In addition, there are continual pressures on ambulatory care expenditure driven by well know 
factors including ageing populations, rising patient expectations and the continued launch of new 
premium priced technologies [2-4]. This has resulted in multiple policies and initiatives among 
authorities across Europe to enhance prescribing efficiency for both new and established medicines 
[2,4]. Policies and initiatives for established medicines include encouraging the prescribing of lower 
cost generics versus originators and patented products in a class where all or nearly all the products 
in the class or related classes are seen as therapeutically similar [1,2,5,6]. Classes include the proton 
pump inhibitors, renin-angiotensin inhibitor drugs as well as the statins [2,5-7]. This takes advantage 
of an increasing number of products losing their patents in recent years [1,2,5,6]. 
 
However as Vogler et al point out, the focus is changing with new premium priced medicines, 
including biological medicines, initiated in hospitals before patients are discharged [1,8]. This is a 
concern for the authorities responsible for ambulatory care if physicians are reluctant to change 
prescriptions to suitable lower cost generics, including generics versus originators, even in countries 
where there is a high rate of prescribing of generics such as Germany [1,8-10]. This is less of an 
issue if there is a tradition of international non-proprietary name (INN) prescribing across all sectors 
(UK) for small molecules [1,6,11], compulsory generic substation (Sweden) [1,6,12], preference 
policies for the molecule (Netherlands) [1,2,13], or reference pricing where patients have to cover the 
additional cost themselves for a more expensive medicine than the quality assured referenced priced 
medicine [1,14]. However, this is an issue if patients are discharged on premium priced medicines, 
including originators, where low cost generics (or branded generics) are equally suitable and there is 
limited potential for switching in ambulatory care, enhanced by hospitals receiving appreciable 
discounts and sometimes free medicines [1,15]. 
 
It was against this background, that the current study was conducted. It was encouraging to see a 
range of countries were studied in this paper with different healthcare systems, different geographies, 
different approaches to the tendering of medicines in hospital as well as different approaches to the 
pricing of generics in ambulatory care and measures to enhance their utilization [1]. In addition, 
concentrating on just one category of medicines, namely cardiovascular medicines, to provide good 
insights for the reasons stated. The study also built on the considerable contacts of the co-authors 
through the PHIS network [1].  
 
The study highlighted a number of interesting findings.  These included the fact that typically hospitals 
only carry one product line, mainly the generic, or at the most two, i.e. both a generic and the 
originator, for a given molecule (only a minority of hospitals in Norway and Slovakia). The only 
exception was atorvastatin where apart from Norway the originator was principally supplied. This 
compares to the ambulatory care sector where there may be multiple presentations available for 
dispensing from different companies once the patent has been lost [1]. One hospital in Portugal only 
carried atorvastatin rather than both simvastatin and atorvastatin [1]. This may reflect previously 
limited demand-side measures in ambulatory care in Portugal preferentially encouraging the 
prescribing of generic simvastatin rather than patented atorvastatin when it first became available 
thereby encouraging the manufacturer of atorvastatin to seek its preferential listing in the hospital 
formulary [1,16]. Secondly, just single doses are often supplied in hospitals versus typically full packs 
in the community with varying tablet sizes and strengths. Thirdly, Norway was the only country in 
which the surveyed medicines were exclusively centrally tendered leading to appreciable discounts. 
This provides an example to other countries, backed up by campaigns supporting generics [1]. There 
was also tendering among hospitals in Portugal, with individual hospitals having the potential to 
negotiate lower prices if able to do so [1]. Discounts of 100% were seen among the majority of 
surveyed hospitals in Austria, although discounts and cost-free medicines did not apply to new on-
patent medicines. Otherwise there was limited headroom for appreciable discounts between the 
hospitals [1]. Dispensing of originators in Austria will increase costs, with Austria having neither INN 
prescribing, generic substitution or reference pricing [1, 17]. However, the Sickness Funds in Austria 
are looking to address this through information and other campaigns in hospitals [1,18]. 
 
In conclusion, this study offers valuable insight into the procurement of generics among hospitals in 
Europe once products lose their patent. It is hoped this study will be repeated for other product 
classes and other countries to provide further insight given the extensive networks and experience of 
the co-authors. This is especially important with growing recognition of the need for both ambulatory 
care and hospital sectors to work more closely together to maximize the health gain of patients with 
available resources ± µ,QWHUIDFH0DQDJHPHQW¶ [1,8]. 
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